A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT07484724 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: JS212
DRUG: JS001
DRUG: 5-FU

Sponsor

Shanghai Junshi Bioscience Co., Ltd.